Publications
Proposed regulations for a unitary SPC for medicinal products under the microscope, Managing IP 2024
Dr. Christian Meyer and Dr. Gisela Grabow of Maiwald consider proposals under the European Commission’s Action Plan for Intellectual Property that aim to simplify extended protection for medicinal products through a unitary supplementary protection certificate.
Continue reading
Interview IAM Strategy 300 Global Leaders, 2024
This year, IAM has once again invited leading experts in the field of intellectual property to provide valuable insights, highlight key experiences and share their views on the current market situation. We are proud that t...
Continue reading
EU pharmaceutical reforms propose changes to regulatory protection periods, Managing IP 2024
Dr. Christian Meyer and Dr. Gisela Grabow discuss potential changes to the EU pharmaceutical regulation and their possible impact on data and market protection timelines for medicinal products.
Continue reading
Year Two – The Unitary Patent and the Unified Patent Court at a Glance, AIPLA Chemical Practice Chronicles Newsletter, Vol. 12 Issue 2, 2024
We can now look back on a quite successful first year of the new European patent and court system. Now well into its second year, the Unitary Patent (UP) continues to grow in popularity and the Unified Patent Court (UPC) is proving itself to be a truly pan-European court. Bo...
Continue reading
Patenting medical treatments in the US and Europe – a guide for practitioners, Managing IP 2024
Dr. Eva Ehlich & Dr. Anja Fux from Maiwald and Eldora Ellison, Paul Calvo & Sara Keeble from Sterne Kessler analyze how patents with claims directed to medical treatments are handled in the US and in Europe.
Continue reading
Women´s IP World Podcast, Episode 2 in Season 4
Our partner Dr.-Ing. Sophie Ertl gives a deep insight in her article from The Women's IP World Annual 2024, which provides a comparative analysis ...
Continue reading
Patent revocation actions under the new European patent system: UPC vs. EPO and why it may be wise to reappraise your European filing strategy, The Patent Lawyer Magazine September/October, 2024 (Page 22)
Continue reading
Die Marktexklusivität als absolutes Recht (Teil II), GRUR 16/2024
Although market exclusivity for orphan drugs (drugs for rare diseases) and the related non-indication-related document and marketing protection are crucial for ensuring investment and innovation protection in the pharmaceutical industry, it has not yet been clarified how and...
Continue reading
Wündisch/Zirkel, F&E-Verträge, Handbuch für Wissenschaft und Praxis, 2024 (German only)
Chapter on the Unified Patent Court and Unitary Patent and on the special features of research and development in the pharmaceutical and life sciences sector
Our colleague Dr. Marco Stief has been given the honor of contributing the chapters on the Unified Patent Court and Unitary Patent as well as on t...
Continue reading
Judgment of the Italian Supreme Court on the so-called Bolar Exemption, 2024 (avialable in English)
Continue reading
Podcast – Empowering women and nurturing young talent: Maiwald’s commitment to equality and diversity, MIP, 2024
Five female patent attorneys at Maiwald, spanning several age groups and practice areas, explain how the intellectual property firm encourages the career development of women and talented young professionals.
Continue reading
Is the medical use disclosure standard different for novelty and sufficiency?, Managing IP, 2024
Eva Ehlich and Anja Fux of Maiwald discuss an EPO board ruling relating to the standard of disclosure concerning the novelty and sufficiency of a therapeutic effec...
Continue reading
Promoting women and young talent at MAIWALD, 2024
Maiwald, a leading German IP law firm, has 45% female partners, emphasizing equality and diversity. The firm supports women's career advancement and attracts talented women through its inclusive culture. Clients, even in m...
Continue reading
Offshore wind power and territoriality principles from a German viewpoint, Managing IP 2024
Claus Schindele considers the legal complications regarding patent protection in the offshore wind sector, with a particular eye on Germany and the UK Patent protection in the offshore wind energy sector i...
Continue reading
Die Marktexklusivität als absolutes Recht (Teil I), GRUR 11/2024
Investment and innovation protection are closely linked in the pharmaceutical sector for the development and marketing of new medicinal products. In addition to patent protection, market exclusivity under pharmaceutical law, which creates a legally defined protection period ...
Continue reading
Unlocking Intellectual Property Efficiency: A comparative analysis of the EP patent, the DE patent, the German Utility Model, and the Unitary Patent, Women´s IP World annual, 2024
Continue reading
European Parliament addresses thorny issue of plants generated by new genomic techniques, Managing IP 4/2024
In her article published by Managing IP, Kerstin Wolff reports on a proposal approved by the European Parliament (EP) that support...
Continue reading
Wettbewerbsrecht im Kontext von Technologietransfer- und Lizenzverträgen, PharmR 4/2024
EU competition law in the context of technology transfer, license and settlement agreements: Since at least the initiation of the first pharma sector inquiry in 2008, the pharma industry has been under close and austere scrutiny of the EU Commission. In the first part of thi...
Continue reading
Reliance on a purported technical effect for inventive step – Quo vadis “plausibility” after G 2/21? epi Information, 1/2024
In the context of the effect-driven assessment of inventive step under the European Patent Convention (EPC) it is usually crucial for the outcome whether an Applicant/a Patentee can rely on a specific technical effect corresponding to an improvement over the prior art. In th...
Continue reading
Not without my consent – Zu den Grenzen des SPC squatting, GRUR 6/2024
SPC for pharmaceutical products are an important complement to patent protection which is often inadequate in commercial terms. SPCs are designed to ensure that originators can amortize their high investments in research and clinical trials. But unlike in the USA, for exampl...
Continue reading
Wettbewerbsrecht im Kontext von F&E- und Linzenzverträgen, PharmR 3/2024
In the trade journal Pharma Recht (46th year, 15 March 2024), Dr. Marco Stief deals with the competition law assessment of research, cooperation and development agreements, with special consideration of the Research and Development Block Exemption Regulation.
Continue reading
§ 945 ZPO – Ausweitung der Haftung der Originatoren bei später widerrufenem Patent?, GRUR 4/2024 (Stief/Meyer)
In a recent article published in GRUR 2024, 182 et seqq., Dr. Marco Stief and
Continue reading
Products eligible for the medical use format under the EPC: new insights, Managing IP 2024
In the latest article published by Managing IP, Dr. Eva Ehlich and Dr. Anja Fux summarise an EPO board ruling relating to substances and compositions in the contex...
Continue reading
T 0116/18 and a review after 10 months of G 2/21, Managing IP 2024
Decision on inventive step casts new light on EBA’s ‘plausibility’ guidance - Dr. Eva Ehlich and Dr. Anja Fux talk about this in the latest article on Managi...
Continue reading
